pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,051 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT814Endpoints614BioPharma Dive237onclive165Fierce Biotech82BioSpace80raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • STAT+: MIT says research has fallen 10%, and grad student enrollment is down
    At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.
    STAT · 2mo ago↗ source
  • Create Medicines raises $122M to bolster in vivo CAR-T therapies
    The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
    BioPharma Dive · 2mo ago↗ source
  • Biogen pushing tau drug forward despite Alzheimer’s study failure
    One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
    BioPharma Dive · 2mo ago↗ source
← prev
page 31 of 43
next →
21
fda recalls20
fda medwatch16
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: BeOne wins FDA approval in lymphoma race
    Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • STAT+: Why big digital health players are missing from Medicare’s chronic care experiment
    In this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
    Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau
    STAT · 2mo ago↗ source
  • With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
    Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Three years of declining overdose deaths begets cautious optimism and some concerns
    The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
    Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
    STAT · 2mo ago↗ source
  • STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
    CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.
    STAT · 2mo ago↗ source
  • STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
    Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.
    STAT · 2mo ago↗ source
  • STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief
    Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the agency.
    STAT · 2mo ago↗ source
  • STAT+: Treatment for alcohol addiction is undergoing a seismic shift. Many say it’s overdue
    The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape. Many say it's overdue.
    STAT · 2mo ago↗ source
  • Opinion: Using AI in addiction medicine could be particularly risky
    "AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," writes Steve D. Klein.
    STAT · 2mo ago↗ source
  • Hantavirus risk remains low, CDC says, citing its ‘playbook’ response
    Despite rising concern about the hantavirus outbreak on a cruise ship, two CDC doctors say the risk to the public remains low.
    STAT · 2mo ago↗ source
  • Officials say $1.3 billion in Medicaid money to California will be deferred over suspicions of fraud
    Vice President JD Vance announced a $1.3 billion deferral in Medicaid reimbursements to California, as part of an initiative to root out fraud in federal health programs.
    STAT · 2mo ago↗ source
  • Opinion: The hantavirus is a wake-up call. Will the Trump administration answer it?
    Arriving in the isolation ward of a biocontainment hospital is an unsettling, scary experience. In 2014, I spent 19 days in one while being treated for Ebola, watching the news…
    STAT · 2mo ago↗ source
  • Opinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisis
    Hospitals and health systems need to loosen the reins and let physicians combat social media misinformation, writes Adam Goodcoff.
    STAT · 2mo ago↗ source
  • STAT+: What the Trump administration wants in its next FDA leader
    Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval reforms.
    STAT · 2mo ago↗ source
  • U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes
    About 70,000 Americans died of drug overdoses last year — about 14% fewer than the previous year, according to preliminary government data.
    STAT · 2mo ago↗ source
  • FDA’s leadership void leaves biotech with renewed ‘uncertainty’
    Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.
    BioPharma Dive · 2mo ago↗ source
  • Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
    A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.
    BioPharma Dive · 2mo ago↗ source
  • Medicare halts enrollment of new hospice, home health providers
    The Centers for Medicare and Medicaid Services said it will pause the enrollment of new hospice and home health providers.
    STAT · 2mo ago↗ source
  • The ‘velocity of obesity’ aims to show which nations are slowing an epidemic
    A study finds the rise in U.S. obesity rates have hit a plateau in children but are still climbing for adults, and are still high compared to those in other…
    STAT · 2mo ago↗ source
  • Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
    Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
    BioPharma Dive · 2mo ago↗ source